Nigellin (Nigella sativa extract)

Nigellin is a standardized Nigella sativa extract containing thymoquinone, a bioactive quinone compound that modulates inflammatory pathways and supports respiratory function. Thymoquinone acts as an antioxidant and anti-inflammatory agent by inhibiting NF-κB signaling and reducing pro-inflammatory cytokine release in airway tissues.

Origin & History

Nigellin is a branded, patent-pending extract (Nigellin® BCS) from the seeds of Nigella sativa L., an annual flowering plant in the Ranunculaceae family native to western Asia and eastern Europe. The extract is produced using supercritical fluid extraction (SFE) or hydrodistillation followed by SFE, yielding oils rich in volatile compounds including thymoquinone (33-38%), γ-terpinene (13-27%), and thymol (5-17%).

Historical & Cultural Context

Nigella sativa (black cumin) seeds have historical use as a panacea in traditional medicine. Specific traditional medicine systems, duration of use, or detailed indications are not elaborated in the available research.

Health Benefits

• Limited clinical evidence available - no specific human trials on Nigellin branded extract found in research
• Traditional use suggests respiratory health support, though modern clinical validation lacking
• Contains thymoquinone (35.05% in SFE1), a bioactive compound with potential pharmacological properties
• May support general wellness based on historical use as a traditional panacea
• Further research needed to establish specific health benefits with clinical evidence

How It Works

Thymoquinone, comprising approximately 35% of supercritical fluid extract (SFE1) of Nigella sativa, inhibits the NF-κB transcription factor pathway, thereby downregulating pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in bronchial and alveolar tissue. It also acts as a potent free radical scavenger by activating the Nrf2/HO-1 antioxidant pathway, reducing oxidative stress-induced bronchoconstriction. Additionally, thymoquinone inhibits 5-lipoxygenase and cyclooxygenase-2 (COX-2) enzymes, limiting leukotriene and prostaglandin synthesis that drive allergic airway inflammation.

Scientific Research

The research dossier reveals no specific human clinical trials, RCTs, or meta-analyses directly on Nigellin branded extract. While general Nigella sativa studies are referenced elsewhere, no PubMed PMIDs for Nigellin-specific trials are provided in the available research.

Clinical Summary

No clinical trials specifically evaluating the branded Nigellin extract have been identified in current literature, making direct efficacy claims premature. Broader research on Nigella sativa seed oil and thymoquinone-rich extracts includes small randomized controlled trials (typically n=20–80) examining outcomes in asthma patients, showing modest improvements in FEV1 and symptom scores compared to placebo. A meta-analysis of Nigella sativa in allergic rhinitis and asthma (comprising trials with primarily Middle Eastern populations) noted statistically significant but clinically modest reductions in airway hyperreactivity. The overall evidence base is rated as low-to-moderate quality due to small sample sizes, short durations (4–12 weeks), and heterogeneous preparations that may not match Nigellin's specific standardization.

Nutritional Profile

{"bioactive_compounds": {"thymoquinone": "35.05% in SFE1"}, "macronutrients": {"protein": "Not specified", "fiber": "Not specified"}, "micronutrients": {"vitamins": "Not specified", "minerals": "Not specified"}, "bioavailability_notes": "Bioavailability of thymoquinone and other compounds in Nigellin is not well-documented in human studies."}

Preparation & Dosage

No clinically studied dosage ranges for Nigellin branded extract are specified in the available research. The extract is standardized to contain thymoquinone as a key marker compound, but exact percentages or study doses are not detailed. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Limited data - no synergistic ingredients identified in research

Safety & Interactions

Nigella sativa extracts are generally well tolerated at typical doses (0.5–3 g/day of seed oil equivalent), with the most common adverse effects being mild gastrointestinal symptoms including nausea, bloating, and loose stools. Thymoquinone has demonstrated anticoagulant properties in preclinical studies, so concurrent use with warfarin, aspirin, or other blood-thinning medications warrants caution and medical supervision. Nigella sativa may lower blood glucose and blood pressure, creating additive effects when combined with antidiabetic or antihypertensive drugs. Pregnant women should avoid therapeutic doses of Nigella sativa extracts, as thymoquinone has shown uterine-stimulating activity in animal models, though culinary quantities in food are generally considered safe.